

eksoBIONICS

Improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function.

Investor Presentation

September 2025



Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and expectations of management with respect to the Company’s industry, growth and strategy, including the Company’s focus on securing more multi-unit orders with large network operators and its ability to obtain sustainable, long-term growth, scale and positive cash flow, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the increase in potential patient population as a result of CMS reimbursement, the expected market opportunities and the Company’s ability to successfully sell its products to such customers and the impacts to patients from the Company’s devices, (v) number or percentage of patients or workers that could potentially benefit from the Company’s products, (vi) potential technological and operational improvements, expected market opportunities and timing and release of certain products, including with the Nomad device and (vii) the assumptions underlying or relating to any statement described in points (i), (ii), (iii), (iv), (v) or (vi) above. Forward-looking statements can be identified by words such as “expect,” “continue,” “anticipate,” “estimate,” “believe,” “plan,” “projection,” “grow,” “potential,” “future,” “can,” “develop,” “proposition,” “position,” “expand” or words of similar meaning. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing to fund and grow the Company’s operations and necessary to develop or enhance the Company’s technology, the significant length of time and resources associated with the development of the Company’s products, the Company’s failure to achieve broad market acceptance of the Company’s products, the failure of the Company’s sales and marketing efforts or of partners to market the Company’s products effectively, adverse results in future clinical studies of the Company’s medical device products, the failure to obtain or maintain patent protection for the Company’s technology, failure to obtain or maintain regulatory approval to market the Company’s medical devices, lack of product diversification, existing or increased competition, disruptions in the Company’s supply chain, the Company’s ability to sell additional units, and, once sold, recognize the expected margins and revenue, using the reimbursement code for our Ekso Indego Personal device with CMS, the Company’s ability to obtain reimbursement from CMS in a timely manner and at the expected reimbursement levels, the Company’s ability to obtain insurance coverage beyond CMS, the Company’s ability to obtain additional indications of use for its devices and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s public filings with the Securities and Exchange Commission (“SEC”). You should carefully read the Cautionary Note Regarding Forward-Looking Statements and the factors described in the “Risk Factors” section of the Company’s public filings with the SEC to better understand the risks and uncertainties inherent in the Company. The Company does not undertake to update these forward-looking statements, except as required by law.

Certain information contained herein has been derived from sources prepared by third parties. While such information is believed to be reliable for the purposes used herein, none of the Company or any of its directors, officers, employees, shareholders, advisors or agents has independently verified the data obtained from these sources or makes any representation or warranty with respect to the accuracy of such information.

Ekso Helps Restore Some of What's Been Lost



Deep Expertise & Industry Leadership



2001 – 2007

Company is Founded out of UC Berkeley

- Initial research grants secured through DARPA
- Contracts focusing on human to machine interface to enhance strength and endurance



2008 – 2012

Ekso Bionics Enters MedTech

- Beginning with an indication for use in Neuro-Rehab for SCI the first Ekso exoskeleton becomes commercially available
- Company name changes to Ekso Bionics



2016 – 2021

NASDAQ Listed & Forges Ahead in Neuro-Rehab

- Globally recognized as a respected name in robotic therapy
- First IDNs signed, paving the way to becoming a standard of care in neuro-rehab



2022 – Present

Market Expansion & Reimbursement

- Acquired Indego from Parker Hannifin Dec 2022
- CMS – April 11, 2024 – Reimbursement of \$91K
- Primary focus moved through building awareness and providing customer education to advancing a scalable go-to-market strategy for the personal channel

500+ centers, 1,000+ devices deployed worldwide

Innovative Wearable Robotics for Health and Daily Life



ENTERPRISE HEALTH

- Neuro-rehabilitation treatment via acute care
- Inpatient rehabilitation hospitals (IRFs)
- Outpatient rehab facilities
- VA medical centers



eksoNR



**eksoINDEGO
THERAPY**



PERSONAL HEALTH

- Home and community use
- Individuals utilizing personal exoskeletons



**eksoINDEGO
PERSONAL**







FUTURE

eksoNOMAD*



In Development – not commercially available. Limited release for research in 2024, commercial release expected in 2025

Existing and Possible Future Indications for Use

EXISTING			eksoHealth			FUTURE Possible Indications
FDA 510(k) Cleared Indications for Use			eksoNR	eksoINDEGO THERAPY	eksoINDEGO PERSONAL	
			ENTERPRISE HEALTH		PERSONAL HEALTH	
	Spinal Cord Injury	20.6M Global ~305K US living with SCI	✓	✓	✓	Parkinson's ~8.5M Global ~1.0M US prevalence
	Stroke	15M Global 800K US cases per year	✓	✓		Guillain-Barre ~150K Global ~5.8K US annual occurrence
	TBI	69M Global 2.9M US cases per year	✓			ALS ~280K Global ~34K US prevalence
	MS	2.5M Global ~1.0M US living with MS	✓			Orthopedic and Post-Surgical Recovery / General Debility ~10M Global ~1.5M US

eksoBIONICS

*Rethinking rehabilitation
with assistive technology*

Enterprise Health



WHY EKSO?

Ekso Helps People Get Back On Their Feet



Proven Rehabilitation Results

- Over a decade of real-world use helping people regain mobility
- Tens of thousands of individuals have taken their first post-injury steps with Ekso
- FDA approved for treatment of: Traumatic Brain Injury (TBI), Stroke, Spinal Cord Injury (SCI), and Multiple Sclerosis (MS)



People Often Walk Out Of An Ekso

- Early high intensity treatment with proper untethered gait training helps restore neuro-plasticity early in treatment
- Applies to TBI, Stroke, partial SCI – Returns people to function for their everyday life



Beyond Rehab: Long-term Care Support

- Function for everyday tasks and reduced overall healthcare costs
- Improved pain management, cardiovascular health, bone density, bowel and bladder function, and mental health



Our Goal Is To Help People Stay On Their Feet

- Taking the first steps with current IFUs, but long-term moving to general debility
- Millions of people can benefit from technology designed to keep them on their feet

Elevating The Standard of Care for Neurorehabilitation

eksoNR



For Patients:

- Untethered environmental engagement promotes neuroplasticity and improved post-stroke outcomes
- Eliminates compensations while walking in the device, elevates precision in movement
- High repetition, increased dosage, and intensity lead to recovery of ambulatory function
- Facilitates task-oriented exercises




For Clinicians:

- Reduces therapist workload and risk of injury to patient/therapist
- GaitCoach software introduced in 2024 promotes ease of use and the potential for better outcomes

Established Global Customer Base

eksoNR

500+ centers, 1,000+ devices deployed worldwide



● Direct
● Distribution

Offices

- ① San Rafael, California - HQ
- ② Brecksville, Ohio
- ③ Düsseldorf, Germany
- ④ Singapore

Economic Value Proposition for EksoNR

Attract New Patients

- Novel technology attracts new patients

Case Study: After introduction of EksoNR, facility saw an 8% increase in volume of stroke patients @ ~\$18,000 per patient

Increase Patient Throughput

- Patients can improve faster, increasing a center's throughput

Case Study: Length of stay in days decreased 14%

Improve Productivity And Efficiency

- Designed for non-ambulatory patients in inpatient setting

Case Study: Single PT can treat low level patients where multiple would be required without the technology


Flexible Acquisition Options

- Financing options for both capital and operational budgets
- Third party financing partners are available

Best Hospitals: 9 centers in top-10, 17 centers in top-25



Still Plenty of Room for Enterprise Health to Grow



New Initiative Launched in Q2-2025

eksoUniversity

Continuing Education Courses (CEU) for
Neurological Physical Therapists

Course Categories



01. All courses



02. Research



03. Spinal Cord Injury



04. Stroke



05. Robotics &
Advance Tech



06. Other Neuro
Diagnoses

eksoBIONICS

Independence on the Go

Personal Health



Expansive Market Growth Across the Care Continuum

eksoHealth

eksoNR

**eksoINDEGO
THERAPY**

**eksoINDEGO
PERSONAL**

ENTERPRISE HEALTH

PERSONAL HEALTH

HOSPITAL

(Ekso Enterprise Health - USA)

HOME

(Ekso Personal Health - USA)



Post Acute
~\$1B



Outpatient
~\$1.9B



Home
~\$13.1B*

Post Acute Neuro-rehab

1,225 Inpatient Rehab Facilities (IRF)
330 Long Term Acute Care Hospitals (LTACH)
18,500 Skilled Nursing Facilities (SNF)

Outpatient Neuro-rehab

52,000 Outpatient Facilities

Mobility

Current reimbursement through VA and CMS (Medicare / Medicaid) for individuals living with a Spinal Cord Injury (SCI)


Our Bodies Are Designed to Stand and Walk

Wheelchair use may be necessary, but it's not without consequence. Prolonged dependence can result in systemic health deterioration.



Cardiovascular System

Poor circulation /
increased DVT risk




Lungs

Reduced capacity



Spine

Postural deformities



Neuropathic Pain

Burning, tingling, or
stabbing sensations



Pressure Sores

Risk of infection, including
sepsis



Bladder / Bowel

Incontinence / frequent
infections



Joint Problems

Osteoporosis / brittle bones



Enabling Independence in the SCI Community

eksoINDEGO



"The Ekso Indego has been a game changer for me. Not only is it a great physical therapy tool that continues to make me stronger, but it also gives me mobility and freedom. In the two months that I have had the Indego I have enjoyed the simple things we take for granted, from standing up to hug my husband, walking around my house and working at our sink looking out our kitchen window. Being able to get out of my wheelchair has given me a hope of feeling normal that is hard to put into words.

– Kim, Indego User

Continuity with Ekso Enterprise Health:

- Individuals with SCI often rehab with Ekso products in Post-Acute Care creating continuity within healthcare systems as they transition to home

Indego's Competitive Advantage

- Fastest known exoskeleton walking speeds
- Ease of use and adaptive intelligence
- Lightest known exoskeleton, modular design
- Transports, dons, and stores easily
- Wireless operation with Indego app



User reported benefits:

- Improved quality of life and mental health
- Improved functional mobility and trunk control
- Improved spasticity, neuropathic pain, bowel and bladder function

Reimbursement Established for Ekso Indego Personal

CMS Rule Change

CMS approved Ekso Indego Personal for lump sum reimbursement of \$91K effective April 1, 2024. Individuals who suffer an SCI typically qualify for Medicare approximately two years after sustaining their injury. The refresh cycle for similar equipment is generally every five years.

- **November 2023** – CMS finalized its Calendar Year 2024 Home Health Prospective Payment System Rule CMS-1780, which includes exoskeletons in the Medicare brace benefit category.
- **December 9, 2023** – Ekso Indego Personal approved under Healthcare Common Procedure Coding System (HCPCS) code # K1007.
- **April 11, 2024** – CMS includes exoskeletons in the Medicare brace benefit category and provided pricing determination of \$91,032 for new claim submissions and retroactively to April 1, 2024.
- **Second Quarter, 2024** – First claim submitted to CMS and received approval for reimbursement.
- **Second Quarter, 2025** – Significant pipeline growth with additional claims being regularly submitted.

Market Size

US SCI PATIENT POPULATION	INCIDENCE	PREVALENCE
Total individuals with SCI	~18,000	~305,000
CMS & VA covered individuals (1.2% VA + 56.6% CMS covered five years post injury)	~10,400	~176,000



Building a Scalable Go-to-Market Strategy


Efficient Market Access Through Partnerships

Leverage Clinical Relationships

- SCI patients rehab with neuro-rehabilitation centers
- Ekso has a major presence in neuro-rehab centers
- Existing clinical customers are referring personal use patients
- Ekso clinics can also benefit from training revenue

Focus On High Value Activities

- Keep operating cost low by leveraging partners
- Ekso provides marketing, equipment, service, and know-how
- Physicians required for medical necessity and prescription
- Third party providers specialize Medicare claims process



Contribution From Personal Health is Growing

Today, Ekso's core Enterprise Health products contribute the majority of Ekso's revenue, but with growing demand and market development for Personal Health products, we believe that contributions from these products will meaningfully increase. Primary drivers:

- CMS pricing determination (2024)
- Engagement of PRIA Healthcare, a leader in market access services (Q4-2024)
- Named National Seating & Mobility as exclusive U.S. distributor of Ekso Indego Personal within the complex rehabilitation industry (Q1-2025)
- Quickly followed by naming Bionic P&O the first orthotic and prosthetic solutions distributor of Ekso Indego Personal in the U.S. (Q2-2025)
- Continuing innovation

eksoBIONICS

Stepping boldly into the future

Transforming Human- Robot Interaction



NVIDIA Connect Program

Advancing ISV Innovation



Building World's First Known Foundation Model for Human Motion

Ekso Bionics' Acceptance into NVIDIA Connect Program Bears Early Fruit



Uniquely Positioned

Current repository consisting of ~350,000 patient sessions and 15 million+ step-by-step data points; growing by an additional 60,000 patient steps on average every day



AI Integration Milestone

Successfully demonstrated initial proof-of-concept in integrating AI-enabled capabilities across portfolio of Enterprise Health and Personal Health exoskeleton devices



AI-Powered Voice Assistance

New AI voice agent ("Ekso Voice Agent") is being designed to support exoskeleton device operation, motivation, training, and safety

eksoBIONICS Positioned for Growth



Broad Product Portfolio

- Reaching a larger addressable market while extending patient care through the continuum of care



Large Market Opportunities

- Well defined, large market opportunities



Reimbursement Expansion

- CMS coverage for SCI patients



Scaling Commercialization

- Strong pipeline and revenue growth potential



AI Innovation

- Transforming human-robot interaction via internal development of new AI-powered capabilities



Upcoming Milestones

- Potential near- and mid-term value inflection points

ekso BIONICS

Thank You!

